Ivivi Technologies Retains Jefferies & Company, Inc. as its Financial Advisor
August 07 2007 - 8:30AM
Business Wire
Ivivi Technologies, Inc. (AMEX:II), a leader in non-invasive,
electrotherapeutic technologies, today announced that it has
retained Jefferies & Company, Inc., the principal operating
subsidiary of Jefferies Group, Inc., as its financial advisor.
Jefferies will act as the Company�s advisor for financings and
business strategy, as well as provide assistance in connection with
the Company�s interest in pursuing strategic partners with
marketing and distribution channels for its products. �We look
forward to working with Jefferies, whose industry expertise will be
invaluable in helping us evaluate opportunities to maximize
shareholder value," said Andr� DiMino, Co-CEO, Ivivi Technologies.
�Jefferies� expertise and well respected position in the capital
markets should assist management in executing its business plan.�
About Jefferies Jefferies, a global investment bank and
institutional securities firm, has served growing and mid-sized
companies and their investors for 45 years. Headquartered in New
York, with more than 25 offices around the world, Jefferies
provides clients with capital markets and financial advisory
services, institutional brokerage, securities research and asset
management. The firm is a leading provider of trade execution in
equity, high yield, convertible and international securities for
institutional investors and high net worth individuals. Jefferies
& Company, Inc. is the principal operating subsidiary of
Jefferies Group, Inc. (NYSE: JEF; www.jefferies.com). Jefferies
International Limited, a UK-incorporated, wholly owned subsidiary
of Jefferies Group, Inc., was established in London in 1985 and is
authorized and regulated by the Financial Services Authority
("FSA"). Jefferies International Limited is a member of the London
Stock Exchange and has Nomad accreditation on the Alternative
Investment Market (AIM), and is also a member of the Deutsche B�rse
(Xetra electronic trading platform), Euronext, Oslo Bors and Dubai
International Financial Exchange (DIFX). Jefferies (Japan) Limited
is a member of the Tokyo Stock Exchange and Jasdaq Securities
Exchange. About Ivivi Technologies, Inc. Based in Northvale, NJ,
Ivivi Technologies, Inc. is a medical technology company focusing
on designing, developing and commercializing its proprietary
electrotherapeutic technology platform. Ivivi�s research and
development activities are focused specifically on pulsed
electromagnetic field, or PEMF, technology, which, by creating a
therapeutic electrical current in injured soft tissue, stimulates
biochemical and physiological healing processes to help repair the
injured tissue and reduce related pain and inflammation. The
Company�s Electroceuticals� have been used in non-invasive
treatments for a wide array of conditions, including chronic
wounds, pain and edema following plastic and reconstructive surgery
and chronic inflammatory disorders. Forward-Looking Statements This
release contains "forward-looking statements" made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995, including the statements related to the preliminary
data discussed above. Forward-looking statements reflect
management's current knowledge, assumptions, judgment and
expectations regarding future performance or events. Although
management believes that the expectations reflected in such
statements are reasonable, they give no assurance that such
expectations will prove to be correct and you should be aware that
actual results could differ materially from those contained in the
forward-looking statements. Forward-looking statements are subject
to a number of risks and uncertainties, including, but not limited
to, the Company�s limited operating history, history of significant
and continued operating losses and substantial accumulated earnings
deficit, difficulties with its financial accounting controls, the
failure of the market for the Company�s products to continue to
develop, the inability for customers to receive third party
reimbursement, the inability to obtain additional capital, the
inability to protect the Company�s intellectual property, the loss
of any executive officers or key personnel or consultants,
competition, changes in the regulatory landscape or the imposition
of regulations that affect the Company�s products and other risks
detailed from time to time in the Company�s filings with the
Securities and Exchange Commission, including the Company�s Annual
Report on Form 10-KSB for the fiscal year ended March 31, 2007. The
Company assumes no obligation to update the information contained
in this press release.
Equifin (AMEX:II)
Historical Stock Chart
From Jun 2024 to Jul 2024
Equifin (AMEX:II)
Historical Stock Chart
From Jul 2023 to Jul 2024